FL-RLS
2.9.2020 00:10:12 CEST | Business Wire | Press release
RLS (USA) Inc. , (Radioisotope Life Sciences ) has purchased General Electric’s (GE) U.S. radiopharmacy network, making it the largest pure molecular imaging focused firm in the United States. Capitor , (www.capitor.co ) a boutique global financial advisory firm, structured and brought the deal to investors, playing a critical part in the years-long negotiation and collaboration between the parties. Financial terms were not disclosed.
The radiopharmacies will continue to supply GE Healthcare molecular imaging products, with RLS leveraging a 10-year distribution partnership agreement. The now privately-owned radiopharmacy network includes a minority ownership by Perceptive Advisors , a $7 billion healthcare specialist investment firm based in New York.
The executive team of RLS is comprised of Chief Executive Officer Werner Gruner , Chief Investment Officer Jaco van Niekerk and Chief Operations Officer Shane Cobb. Mr. Gruner, who has served as executive in various roles within the international financial industry, including the founding of Capitor, comments that “I was intrigued and excited about the possibilities of this healthcare acquisition, beyond the financial aspects of the transaction. I have spent my career providing white-glove investment advisory services to global clients and always believed that customers, no matter the industry, not only deserve, but have a right to demand personalized, timely, high-end service,” adding, “that is why we focus on service, quality and disruptive technology as key factors in our investment strategy.”
The radiopharmacy network includes 31 pharmacies across 18 states, including its current headquarters in Tampa, Florida. Under the direction of Mr. van Niekerk, RLS aims to invest $2 billion over the next decade in expanding its footprint of pharmacies, while continuously investing in cutting-edge scientific and technological advancements. “We invested considerable efforts to ensure a seamless transition precisely because of our service-centric philosophy, including retaining key executive staff, such as Shane Cobb who has more than 30 years of experience in the industry,” stated Mr. van Niekerk, concluding that “RLS is committed to delivering life-saving quality diagnostics and treatment to patients across the nation. To that end, and in light of what we are uncovering regarding the potential long-term effects of organ damage caused by COVID-19, we have instituted a special task force focused on accommodating what could be a surge in demand for specialized diagnostic services.”
Almost five-hundred former GE employees across the country are now part of the RLS family. The company is expected to relocate its headquarters to the east coast of Florida in the near future and is in conversations with various economic development councils as well as municipalities.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200901006104/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press release
Barilla continues to advance its commitment to tastier products with less sugar and salt;An investment of 30 million euros in 2025 to quadruple photovoltaic capacity across plants, as part of a €168 million five-year plan focused on energy efficiency, renewable energy and sustainable water management.Barilla continues to expand regenerative agriculture practices across its global value chain, with over 816,000 tons of raw materials sourced through the Barilla Sustainable Farming program.4,000 tons of products donated worldwide and €2 million allocated to social causes in 2025, supporting communities across Barilla’s global footprint through food donations and social initiatives. A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal oppor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
